2021 Antibacterial agents in clinical and preclinical development PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download 2021 Antibacterial agents in clinical and preclinical development PDF full book. Access full book title 2021 Antibacterial agents in clinical and preclinical development by World Health Organization. Download full books in PDF and EPUB format.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240047654
Category : Business & Economics
Languages : en
Pages : 104
Get Book Here
Book Description
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240047654
Category : Business & Economics
Languages : en
Pages : 104
Get Book Here
Book Description
Author: Thomas J. Dougherty
Publisher: Springer Science & Business Media
ISBN: 1461414008
Category : Medical
Languages : en
Pages : 1119
Get Book Here
Book Description
This volume covers all aspects of the antibiotic discovery and development process through Phase II/III. The contributors, a group of highly experienced individuals in both academics and industry, include chapters on the need for new antibiotic compounds, strategies for screening for new antibiotics, sources of novel synthetic and natural antibiotics, discovery phases of lead development and optimization, and candidate compound nominations into development. Beyond discovery , the handbook will cover all of the studies to prepare for IND submission: Phase I (safety and dose ranging), progression to Phase II (efficacy), and Phase III (capturing desired initial indications). This book walks the reader through all aspects of the process, which has never been done before in a single reference. With the rise of antibiotic resistance and the increasing view that a crisis may be looming in infectious diseases, there are strong signs of renewed emphasis in antibiotic research. The purpose of the handbook is to offer a detailed overview of all aspects of the problem posed by antibiotic discovery and development.
Author: National Academies Of Sciences Engineeri
Publisher: National Academies Press
ISBN: 9780309269452
Category : Medical
Languages : en
Pages :
Get Book Here
Book Description
The National Strategy for Combating Antibiotic Resistant Bacteria, published in 2014, sets out a plan for government work to mitigate the emergence and spread of resistant bacteria. Direction on the implementation of this strategy is provided in five-year national action plans, the first covering 2015 to 2020, and the second covering 2020 to 2025. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine evaluates progress made against the national strategy. This report discusses ways to improve detection of resistant infections and estimate the risk to human health from environmental sources of resistance. In addition, the report considers the effect of agricultural practices on human and animal health and animal welfare and ways these practices could be improved, and advises on key drugs and diseases for which animal-specific test breakpoints are needed.
Author: Prashant Kesharwani
Publisher: Academic Press
ISBN: 0128184809
Category : Medical
Languages : en
Pages : 432
Get Book Here
Book Description
Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included. Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309185548
Category : Medical
Languages : en
Pages : 397
Get Book Here
Book Description
Infectious diseases are a global hazard that puts every nation and every person at risk. The recent SARS outbreak is a prime example. Knowing neither geographic nor political borders, often arriving silently and lethally, microbial pathogens constitute a grave threat to the health of humans. Indeed, a majority of countries recently identified the spread of infectious disease as the greatest global problem they confront. Throughout history, humans have struggled to control both the causes and consequences of infectious diseases and we will continue to do so into the foreseeable future. Following up on a high-profile 1992 report from the Institute of Medicine, Microbial Threats to Health examines the current state of knowledge and policy pertaining to emerging and re-emerging infectious diseases from around the globe. It examines the spectrum of microbial threats, factors in disease emergence, and the ultimate capacity of the United States to meet the challenges posed by microbial threats to human health. From the impact of war or technology on disease emergence to the development of enhanced disease surveillance and vaccine strategies, Microbial Threats to Health contains valuable information for researchers, students, health care providers, policymakers, public health officials. and the interested public.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240052453
Category : Medical
Languages : en
Pages : 92
Get Book Here
Book Description
Author: I.W. Fong
Publisher: Springer Science & Business Media
ISBN: 0387724184
Category : Medical
Languages : en
Pages : 411
Get Book Here
Book Description
This comprehensive, up-to-date volume defines the issues and offers potential solutions to the challenges of antimicrobial resistance. The chapter authors are leading international experts on antimicrobial resistance among a variety of bacteria, viruses including HIV and herpes, parasites and fungi. The chapters explore the molecular mechanisms of drug resistance, the immunology and epidemiology of resistance strains, clinical implications and implications on research and lack thereof, and prevention and future directions.
Author: Stephen T. Abedon
Publisher: Frontiers Media SA
ISBN: 2889452514
Category :
Languages : en
Pages : 394
Get Book Here
Book Description
Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309498511
Category : Medical
Languages : en
Pages : 103
Get Book Here
Book Description
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
Author:
Publisher: World Health Organization
ISBN: 9240021302
Category : Business & Economics
Languages : en
Pages : 76
Get Book Here
Book Description
This report is the World Health Organization’s (WHO) fourth annual review of the clinical antibacterial pipeline, and the second review of the preclinical antibacterial pipeline. The WHO’s annual antibacterial pipeline report reviews antibiotics that are in the clinical stages of development as well as those in early development to assess the progress and gaps in relation to urgent threat of drug-resistance.The report evaluates the potential of these antibacterial candidates in development to address the most threatening drug-resistant bacteria as outlined in the WHO Bacterial Priority Pathogens List (WHO PPL). This report covers direct-acting small molecules and biological agents that are in development worldwide. In this fourth edition, the report includes for the first time a comprehensive overview of non-traditional antibacterial medicines. This report is part of the WHO’s efforts in global research and development (R&D) priority setting to contain antimicrobial resistance. All the data contained in this report can be downloaded from the WHO Global Observatory on Health R&D.
